News
06-04-2010, 06:02 AM
Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.
More... (http://www.news-medical.net/news/20100604/Antiemetic-regimen-with-fosaprepitant-injection-provides-similar-protection-against-CINV-as-oral-EMEND.aspx)
More... (http://www.news-medical.net/news/20100604/Antiemetic-regimen-with-fosaprepitant-injection-provides-similar-protection-against-CINV-as-oral-EMEND.aspx)